Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-Sud University, Villejuif, France; Medical Oncology I, Fondazione Del Piemonte Per L'Oncologia, IRCCS, Turin, Italy.
Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-Sud University, Villejuif, France; Université Paris-Sud, F-94085 Villejuif, France; Institut National de La Santé Et de La Recherche Médicale (INSERM) U1015, Villejuif, France; Equipe Labellisée-Ligue Nationale Contre le Cancer, Villejuif, France.
Eur J Cancer. 2019 Jan;107:79-85. doi: 10.1016/j.ejca.2018.10.023. Epub 2018 Dec 11.
Bone metastases (BMs) are associated with significant morbidity and shorter survival in renal cell carcinoma (RCC). Our purpose was to identify prognostic factors for overall survival (OS) in RCC patients with BMs.
Data from patients with BMs from RCC treated at Gustave Roussy between April 1992 and March 2016 were retrospectively collected. Age, sex, Eastern Cooperative Oncology Group-Performance Status, Memorial Sloan-Kettering Cancer Center (MSKCC) risk groups, histology, number and site of bone lesions, concomitant metastases (presence and sites), therapy for BMs (radical resection or palliative surgery, radiotherapy and other local and systemic treatments) and time from diagnosis to BMs were analysed. Synchronous solitary bone metastasis (SSBM) was defined as a single BM without concomitant visceral lesions at the initial diagnosis of RCC. OS was calculated from the date of BMs diagnosis to death or last follow-up using Kaplan-Maier method and modelled with Cox regression analysis.
From 1750 patients with diagnosis of RCC followed at Gustave Roussy Cancer Campus, 300 patients with BMs were identified. Median time from diagnosis to BMs was 32.4 months (range 0-324 months). In 64 patients (21%), bone was the only metastatic site, and 22 patients (7%) had an SSBM and 236 patients (79%) had concomitant metastases in other sites. Median OS was 23.2 months (95% confidence interval 19.9-26.2). SSBM patients had better OS than those with concomitant metastases (40 vs 20 months; P < 0.001). At multivariate analysis, concomitant metastases remained predictor of poor prognosis, while MSKCC risk group, radical resection and SSBM were predictors of better OS.
This study suggests that MSKCC score, numbers of BMs and radical resection are important prognostic factors for RCC patients with BMs. Additionally, in the presence of solitary BM without concomitant metastases at the initial diagnosis of RCC, bone surgery should be considered to achieve local tumour control and likely increase OS.
骨转移(BMs)与肾细胞癌(RCC)患者的显著发病率和较短的生存期相关。我们的目的是确定 RCC 伴 BMs 患者总生存期(OS)的预后因素。
回顾性收集了 1992 年 4 月至 2016 年 3 月在 Gustave Roussy 治疗的伴 BMs 的 RCC 患者的数据。分析了年龄、性别、东部合作肿瘤组体能状态、纪念斯隆-凯特琳癌症中心(MSKCC)风险组、组织学、骨病变的数量和部位、同时存在的转移灶(存在和部位)、BMs 的治疗(根治性切除术或姑息性手术、放疗和其他局部及全身治疗)以及从诊断到 BMs 的时间。同步单发骨转移(SSBM)定义为在初始诊断为 RCC 时仅有单个 BM 而无同时存在的内脏病变。采用 Kaplan-Meier 法计算从 BMs 诊断到死亡或最后一次随访的 OS,并采用 Cox 回归分析进行建模。
在 Gustave Roussy 癌症园区接受 RCC 随访的 1750 例患者中,有 300 例患者被诊断为 BMs。从诊断到 BMs 的中位时间为 32.4 个月(范围 0-324 个月)。在 64 例(21%)患者中,骨是唯一的转移部位,22 例(7%)患者有 SSBM,236 例(79%)患者在其他部位有同时存在的转移灶。中位 OS 为 23.2 个月(95%置信区间 19.9-26.2)。SSBM 患者的 OS 优于同时存在转移灶的患者(40 个月 vs 20 个月;P<0.001)。多变量分析显示,同时存在转移灶仍然是预后不良的预测因素,而 MSKCC 风险组、根治性切除术和 SSBM 是 OS 更好的预测因素。
本研究表明,MSKCC 评分、BMs 的数量和根治性切除术是 RCC 伴 BMs 患者的重要预后因素。此外,在初始诊断为 RCC 时存在无同时存在转移灶的单发 BM 时,应考虑进行骨手术以实现局部肿瘤控制,并可能增加 OS。